Journal
FUTURE ONCOLOGY
Volume 13, Issue 2, Pages 159-174Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2016-0289
Keywords
breast carcinoma; HRR pathway; neoadjuvant chemotherapy
Categories
Funding
- UGC-NET Fellowship grant [F.2-3/2000, 2061030813, 20-06/2010(i) EU-IV]
- CSIR RA grant [09/030(0071)/2013-EMR-I (RA)]
- DST Fast Track [SR/FT/LS-81/2009]
Ask authors/readers for more resources
Aim: To understand the importance of homologous recombination repair pathway in development of breast carcinoma (BC), alterations of some key regulatory genes like BRCA1, BRCA2, FANCC and FANCD2 were analyzed in pretherapeutic/neoadjuvant chemotherapy (NACT)-treated BC samples. Materials & methods: Alterations (deletion/methylation/ expression) of the genes were analyzed in 118 pretherapeutic and 41 NACT-treated BC samples. Results: High deletion/methylation (29-68%) and 64-78% overall alterations of the genes were found in the samples. Concordance was evident between alteration and protein expression of the genes. Estrogen/progesterone receptor-negative tumors showed significantly high alterations even in NACT-treated samples having low CD44 and proliferating cell nuclear antigen expression. Pretherapeutic patients with alterations showed poor prognosis. Conclusion: Alterations of homologous recombination repair pathway genes are needed for the development of BC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available